Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy

Journal of Medicinal Chemistry

Volumn 51, Issue 6, 2008, Pages 1740-1746

  Leu, Yu Ling ^a   Chen, Chien Shu ^b   Wu, Yih Jang ^b   Chern, Ji Wang ^b  

^a CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

10 [4 (BETA DEXTRO GLUCURONYLOXY) 3 NITROBENZYLOXYL]CAMPTOTHECIN; 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; BETA GLUCURONIDASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG STABILITY; DRUG STRUCTURE; ESCHERICHIA COLI; HUMAN; HUMAN CELL; TUMOR CELL;

ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CAMPTOTHECIN; CATALYSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ESCHERICHIA COLI; GLUCURONIDASE; GLUCURONIDES; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; PHENYL ETHERS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41149117548     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701151c     Document Type: Article

References (45)

1. Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmar, K. H.; McPhail, A. T.; Sim, G. A. Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Acuminata. J. Am. Chem. Soc. 1966, 88, 3888-3890.
2. Hsiang, Y.-H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985, 260, 14873-14878.
3. Kingsbury, W. D.; Boehm, J. C.; Jakas, D. R.; Holden, K. G.; Hecht, S. M.; Gallagher, G.; Caranfa, M. J.; McCabe, F. L.; Faucette, L. F.; Johnson, R. K.; Hertzberg, R. P. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem. 1991, 34, 98-107.
4. Sawada, S.; Okajima, S.; Aiyama, R.; Nokata, K.; Furuta, T.; Yokokura, T.; Sugino, E.; Yamaguchi, K.; Miyasaka, T. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem. Pharm. Bull. 1991, 39, 1446-1450.
5. Wani, M. C.; Wall, M. E. Plant antitumor agents. II. The structure of two new alkaloids from Camptotheca acuminata. J. Org. Chem. 1969, 34, 1364-1367.
6. Wani, M. C.; Ronman, P. E.; Lindley, J. T.; Wall, M. E. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J. Med. Chem. 1980, 23, 554-560.
7. Kawato, Y.; Aonuma, M.; Hirota, Y. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991, 51, 4187-4191.
8. Ahmed, F.; Vyas, V.; Cornfield, A.; Goodin, S.; Ravikumar, T. S.; Rubin, E. H.; Gupta, E. In vitro activation of irinotecan to SN-38 by human liver and intestine. Anticancer Res. 1999, 19, 2067-2071.
9. Leu, Y.-L.; Roffler, S. R.; Chern, J.-W. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). J. Med. Chem. 1999, 42, 3623-3628.
10. Paigen, K. Mammalian beta-glucuronidase: genetics, molecular biology, and cell biology. Prog. Nucleic Acid Res. Mol. Biol. 1989, 37, 155-205.
11. Bosslet, K.; Straub, R.; Blumrich, M.; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H. K.; Gesson, J.-P.; Koch, M.; Monneret, C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 1998, 58, 1195-1201.
12. Bosslet, K.; Czech, J.; Hoffmann, D. A novel one-step tumor-selective prodrug activation system. Tumor Targeting 1995, 1, 45-50.
13. Chen, X.; Wu, B.; Wang, P. G. Glucuronides in anti-cancer therapy. Curr. Med. Chem.: Anti-Cancer Agents 2003, 3, 139-150.
14. Alaoui, A. E.; Saha, N.; Schmidt, F.; Monneret, C.; Florent, J.-C. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy. Bioorg. Med. Chem. 2006, 14, 5012-5019.
15. Skwarczynski, M.; Hayashi, Y.; Kiso, Y. Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J. Med. Chem. 2006, 49, 7253-7269.
16. 6-benzyl-2′-deoxyguanosine. J. Med. Chem. 2005, 48, 256-261.
17. Prijovich, Z. M.; Chen, B.-M.; Leu, Y.-L.; Chern, J.-W.; Roffler, S. R. Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. Br. J. Cancer 2002, 86, 1634-1638.
18. Prijovich, Z. M.; Leu, Y.-L.; Roffler, S. R. Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin. Biochem. Pharmacol. 2003, 66, 1181-1187.
19. Prijovich, Z. M.; Leu, Y.-L.; Roffler, S. R. Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin. Cancer Chemother. Pharmacol. 2007, 60, 7-17.
20. Chen, K.-C.; Cheng, T.-L.; Leu, Y.-L.; Prijovich, Z. M.; Chuang, C.-H.; Chen, B.-M.; Roffler, S. R. Membrane-localized activation of glucuronide prodrugs by β-glucuronidase enzymes. Cancer Gene Ther. 2007, 14, 187-200.
21. Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Manikumar, G.; Tele, C.; Moore, L.; Truesdale, A.; Leitner, P.; Besterman, J. M. Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J. Med. Chem. 1993, 36, 2689-2700.
22. Ling, Y. H.; Andersson, B. S.; Nelson, J. A. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells. Cancer Biochem. Biophys. 1990, 11, 23-30.
23. Han, R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 1994, 12, 53-63.
24. Zhang, R.; Cai, Q.; Lindsey, J. R.; Li, Y.; Chambless, B.; Naguib, F. N. M. Antitumor activity and pharmacokinetics following oral administration of natural product DNA topoisomerase I inhibitors 10-hydroxycamptothecin and camptothecin in SCID mice bearing human breast cancer xenografts. Int. J. Oncol. 1997, 10, 1147-1156.
25. Zhou, J.-J.; Liu, J.; Xu, B. Relationship between lactone ring forms of HCPT and their antitumor activities. Acta Pharmacol. Sin. 2001, 22, 827-830.
26. Mattern, M. R.; Hofmann, G. A.; Polsky, R. M.; Funk, L. R.; McCabe, F. L.; Johnson, R. K. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol. Res. 1993, 5, 467-474.
27. Wang, Y.; Li, L.; Jiang, W.; Larrick, J. W. Synthesis and evaluation of a DHA and 10-hydroxycamptothecin conjugate. Bioorg. Med. Chem. 2005, 13, 5592-5599.
28. Takayama, H.; Watanabe, A.; Hosokawa, M.; Chiba, K.; Satoh, T.; Aimi, N. Synthesis of a new class of camptothecin derivatives, the long-chain fatty acid esters of 10-hydroxycamptothecin, as a potent prodrug candidate, and their in vitro metabolic conversion by carboxylesterases. Bioorg. Med. Chem. Lett. 1998, 8, 415-418.
29. Greenwald, R. B.; Pendri, A.; Choe, Y. H. Acyl Polymeric Derivatives of Aromatic Hydroxyl-Containing Compounds. U.S. Patent 6,011,042, 2000.
30. He, X.; Lu, W.; Jiang, X.; Cai, J.; Zhang, X.; Ding, J. Synthesis and biological evaluation of bis and monocarbonate prodrugs of 10- hydroxycamptothecins. Bioorg. Med. Chem. 2004, 12, 4003-4008.
31. Toki, B. E.; Cerveny, C. G.; Wahl, A. F.; Senter, P. D. Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. J. Org. Chem. 2002, 67, 1866-1872.
32. Haisma, H. J.; van Muijen, M.; Pinedo, H. M.; Boven, E. Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody - β-glucuronidase conjugate in the specific treatment of cancer. Cell Biophys. 1994, 24-25, 185-192.
33. Florent, J. C.; Dong, X.; Gaudel, G.; Mitaku, S.; Monneret, C.; Gesson, J. P.; Jacquesy, J. C.; Mondon, M.; Renoux, B.; Andrianomenjanahary, S.; Michel, S.; Koch, M.; Tillequin, F.; Gerken, M.; Czech, J.; Straub, R.; Bosslet, K. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J. Med. Chem. 1998, 41, 3572-3581.
34. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1-28.
35. Duimstra, J. A.; Femia, F. J.; Meade, T. J. A gadolinium chelate for detection of β-glucuronidase: a self-immolative approach. J. Am. Chem. Soc. 2005, 127, 12847-12855.
36. Tosin, M.; Murphy, P. V. Synthesis of α-glucuronic acid and amide derivatives in the presence of a participating 2-acyl protecting group. Org. Lett. 2002, 4, 3675-3678.
37. Fassberg, J.; Stella, V. J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 1992, 81, 676-684.
38. De Graaf, M.; Boven, E.; Scheeren, H. W.; Haisma, H. J.; Pinedo, H. M. Beta-glucuronidase-mediated drug release. Curr. Pharm. Des. 2002, 8, 1391-1403.
39. Wang, R.; Gao, Y.; Lai, L. Calculating partition coefficient by atom-additive method. Persped. Drug Discovery Des. 2000, 19, 47-66.
40. Angenault, S.; Thirot, S.; Schmidt, F.; Monneret, C.; Pfeiffer, B.; Renard, P. Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (prodrug monotherapy) strategy. Bioorg. Med. Chem. Lett. 2003, 13, 947-950.
41. Jain, S.; Drendel, W. B.; Chen, Z. W.; Mathews, F. S.; Sly, W. S.; Grubb, J. H. Structure of human β-glucuronidase reveals candidate lysosomal targeting and active-site motifs. Nat. Struct. Biol. 1996, 3, 375-381.
42. Katu, K.; Yoshida, K.; Tsukannto, H. Synthesis of p-nitrophenyl β-D-glucopyranosiduronic acid and its utilization as a substrate for the assay of β-glucuronidase activity. Chem. Pharm. Bull. 1960, 8, 239-242.
43. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
44. Islam, M. R.; Tomatsu, S.; Shah, G. N.; Grubb, J. H.; Jain, S.; Sly, W. S. Active site residues of human β-glucuronidase. Evidence for Glu540 as the nucleophile and Glu451 as the acid-base residue. J. Biol. Chem. 1999, 274, 23451-23455.
45. Geddie, M. L.; Matsumura, I. Rapid evolution of β-glucuronidase specificity by saturation mutagenesis of an active site loop. J. Biol. Chem. 2004, 279, 26462-26468.